IDEAYA Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yujiro S. Hata
- Full Time Employees
- 145
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7000 Shoreline Court South San Francisco CA United States of America 94080
- IPO Date
- May 23, 2019
- CIK
- 0001676725
- Website
- ideayabio.com
- Similar Companies
- Business
- IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics principally in precision oncology. The company’s core product pipeline includes small-molecule drugs and antibody-drug conjugates (ADCs) centered around synthetic lethality and biomarkers-driven patient selection. Key products in clinical development include darovasertib (IDE196), a protein kinase C (PKC) inhibitor for tumors with GNAQ or GNA11 mutations such as uveal melanoma; IDE397, a methionine adenosyltransferase 2A (MAT2A) inhibitor targeting cancers with MTAP gene deletions; IDE161, a poly(ADP-ribose) glycohydrolase (PARG) inhibitor for tumors with homologous recombination deficiency (HRD); and IDE034, a bispecific B7H3/PTK7 TOP1 antibody-drug conjugate designed for solid tumors expressing these targets. IDEAYA employs integrated biomarker and small molecule drug discovery platforms and collaborates with leading pharmaceutical companies to advance its pipeline globally. The company operates primarily out of South San Francisco, California, and was founded to leverage synthetic lethality approaches to selectively target cancer vulnerabilities while sparing normal cells. Recent major corporate developments include strategic partnerships and collaborations with pharmaceutical companies such as GlaxoSmithKline (GSK), which focuses on IDEAYA’s synthetic lethality programs including MAT2A, Pol Theta, and Werner Helicase, with shared development costs and profit-sharing arrangements. Partnership with Gilead centers on the IDE397 program, and a collaboration with Pfizer supports development of darovasertib. Additionally, in September 2025, IDEAYA entered a global licensing and collaboration agreement with Servier, under which Servier obtained rights to darovasertib outside the U.S., bringing in $210 million upfront plus up to $320 million in milestones, expanding the commercial and clinical development reach of this program worldwide. In December 2025, the U.S. Food and Drug Administration cleared IDEAYA’s investigational new drug application for IDE034, initiating a Phase 1 clinical trial enrolling patients in the first quarter of 2026 targeting multiple solid tumors including lung, colorectal, head and neck, and ovarian cancers. These recent advances underscore IDEAYA’s commitment to advancing potentially first-in-class, precision-guided oncology therapies and expanding its clinical pipeline while strategically leveraging partnerships to enhance global development and commercialization efforts.
Company News
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late